Compare Equinor ASA (EQNR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Eli Lilly And Co — how do they compare? Equinor ASA trades at $43 (market cap $101.62B), while Eli Lilly And Co trades at $1,169 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 10.2× Equinor ASA's market cap, and Equinor ASA pays the higher dividend (3.63%). Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Eli Lilly And Co for 93 Days on average.
| EQNR | LLY | |
|---|---|---|
Market Cap | $101.62B | $1.04T |
Volume | 4,991,782 | 3,064,878 |
Sector | Energy | Health |
52-Week High | $45.75 | $1.28K |
52-Week Low | $22.41 | $799.57 |
Typical Hold Time | 59 Days | 93 Days |
Enterprise Value | $110.31B | $1.09T |
Dividend Yield | 3.63% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $41.61, down 3.26% today, with a bearish technical signal despite strong valuation metrics including a P/E of 11.28 and EV/EBITDA of 2.35. The company has beaten earnings estimates in two of the last three quarters, with Q3 2026 results pending. Recent news highlights expansion in LNG and carbon capture projects, while cash flow trends show improving operational performance from 2025 levels.
EQNR presents a compelling value opportunity with significant upside to the $70.50 consensus price target, though near-term technical weakness and declining profit margins from 2022 peaks pose risks. The stock's 21.32% ROE and dividend payments support income investors, while LNG expansion plans provide growth catalysts. Market sentiment remains mixed with 30% buy ratings amid energy sector volatility.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
